{"title":"糖尿病肾病的表型异质性及其与心血管和肾脏预后的关系:来自中国多中心队列研究的证据","authors":"Yi Li, Zuhai Hu, Liping Chen, Huichang Jia, Weili Wang, Shiyu Zhou, Xin Xu, Huhai Zhang, Hongwen Zhao","doi":"10.1111/dom.71239","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Diabetic kidney disease (DKD), a major microvascular complication of diabetes, is the leading cause of chronic kidney disease (CKD) and progression to end-stage kidney disease (ESKD). DKD exhibits substantial clinical heterogeneity, ranging from the classic proteinuric phenotype to the increasingly recognised nonproteinuric phenotype. However, cardiovascular, kidney and all-cause mortality risks across these phenotypes remain incompletely characterised.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of 14 367 adults with DKD in the China Renal Data System (CRDS). Major adverse cardiovascular events (MACEs), ESKD and all-cause mortality were ascertained from longitudinal electronic health records. Multi-state models were used to characterise transitions among clinical states and to estimate transition-specific risks across DKD phenotypes.</p><p><strong>Results: </strong>Over a median follow-up of 2.1 years, 17.1% of participants experienced MACE, while 7.0% and 10.0% progressed to ESKD and experienced all-cause mortality, respectively. High urinary albumin-to-creatinine ratio (UACR)-related phenotypes emerged as persistent risk factors across various disease trajectories. In particular, the phenotype combining low estimated glomerular filtration rate (eGFR) and high UACR had the highest risks of progression to ESKD and of death after MACE.</p><p><strong>Conclusions: </strong>Our findings show that DKD phenotypes defined by baseline eGFR and UACR were associated with distinct cardiovascular, kidney and mortality risks. Albuminuria remained an important prognostic marker even when eGFR was preserved, whereas the combination of low eGFR and high albuminuria identified the highest risk group. These findings support improved phenotypic risk stratification and may inform future clinical research and individualised risk assessment in DKD.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10248-10260"},"PeriodicalIF":6.1000,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Phenotypic Heterogeneity of Diabetic Kidney Disease and Its Association With Cardiovascular and Renal Outcomes: Evidence From a Chinese Multicentre Cohort.\",\"authors\":\"Yi Li, Zuhai Hu, Liping Chen, Huichang Jia, Weili Wang, Shiyu Zhou, Xin Xu, Huhai Zhang, Hongwen Zhao\",\"doi\":\"10.1111/dom.71239\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Diabetic kidney disease (DKD), a major microvascular complication of diabetes, is the leading cause of chronic kidney disease (CKD) and progression to end-stage kidney disease (ESKD). DKD exhibits substantial clinical heterogeneity, ranging from the classic proteinuric phenotype to the increasingly recognised nonproteinuric phenotype. However, cardiovascular, kidney and all-cause mortality risks across these phenotypes remain incompletely characterised.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of 14 367 adults with DKD in the China Renal Data System (CRDS). Major adverse cardiovascular events (MACEs), ESKD and all-cause mortality were ascertained from longitudinal electronic health records. Multi-state models were used to characterise transitions among clinical states and to estimate transition-specific risks across DKD phenotypes.</p><p><strong>Results: </strong>Over a median follow-up of 2.1 years, 17.1% of participants experienced MACE, while 7.0% and 10.0% progressed to ESKD and experienced all-cause mortality, respectively. High urinary albumin-to-creatinine ratio (UACR)-related phenotypes emerged as persistent risk factors across various disease trajectories. In particular, the phenotype combining low estimated glomerular filtration rate (eGFR) and high UACR had the highest risks of progression to ESKD and of death after MACE.</p><p><strong>Conclusions: </strong>Our findings show that DKD phenotypes defined by baseline eGFR and UACR were associated with distinct cardiovascular, kidney and mortality risks. Albuminuria remained an important prognostic marker even when eGFR was preserved, whereas the combination of low eGFR and high albuminuria identified the highest risk group. These findings support improved phenotypic risk stratification and may inform future clinical research and individualised risk assessment in DKD.</p>\",\"PeriodicalId\":158,\"journal\":{\"name\":\"Diabetes, Obesity & Metabolism\",\"volume\":\" \",\"pages\":\"10248-10260\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2026-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes, Obesity & Metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/dom.71239\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2026/8/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dom.71239","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/17 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Phenotypic Heterogeneity of Diabetic Kidney Disease and Its Association With Cardiovascular and Renal Outcomes: Evidence From a Chinese Multicentre Cohort.
Background: Diabetic kidney disease (DKD), a major microvascular complication of diabetes, is the leading cause of chronic kidney disease (CKD) and progression to end-stage kidney disease (ESKD). DKD exhibits substantial clinical heterogeneity, ranging from the classic proteinuric phenotype to the increasingly recognised nonproteinuric phenotype. However, cardiovascular, kidney and all-cause mortality risks across these phenotypes remain incompletely characterised.
Methods: We conducted a retrospective cohort study of 14 367 adults with DKD in the China Renal Data System (CRDS). Major adverse cardiovascular events (MACEs), ESKD and all-cause mortality were ascertained from longitudinal electronic health records. Multi-state models were used to characterise transitions among clinical states and to estimate transition-specific risks across DKD phenotypes.
Results: Over a median follow-up of 2.1 years, 17.1% of participants experienced MACE, while 7.0% and 10.0% progressed to ESKD and experienced all-cause mortality, respectively. High urinary albumin-to-creatinine ratio (UACR)-related phenotypes emerged as persistent risk factors across various disease trajectories. In particular, the phenotype combining low estimated glomerular filtration rate (eGFR) and high UACR had the highest risks of progression to ESKD and of death after MACE.
Conclusions: Our findings show that DKD phenotypes defined by baseline eGFR and UACR were associated with distinct cardiovascular, kidney and mortality risks. Albuminuria remained an important prognostic marker even when eGFR was preserved, whereas the combination of low eGFR and high albuminuria identified the highest risk group. These findings support improved phenotypic risk stratification and may inform future clinical research and individualised risk assessment in DKD.
期刊介绍:
Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.